P-Sam
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenoid Cystic Carcinoma
Conditions
Adenoid Cystic Carcinoma
Trial Timeline
Dec 28, 2026 → Dec 31, 2031
NCT ID
NCT07162480About P-Sam
P-Sam is a phase 2 stage product being developed by AstraZeneca for Adenoid Cystic Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07162480. Target conditions include Adenoid Cystic Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07162480 | Phase 2 | Recruiting |
Competing Products
11 competing products in Adenoid Cystic Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab Vedotin | Astellas Pharma | Phase 2 | 52 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Lenvatinib + Pembrolizumab | Eisai | Phase 2 | 52 |
| Cetuximab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Dovitinib | Novartis | Phase 2 | 52 |
| Dovitinib (TKI258) | Novartis | Phase 2 | 52 |
| AG-013736 (AXITINIB) | Pfizer | Phase 2 | 51 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Mometasone Furoate nasal spray + Placebo | Organon | Phase 3 | 72 |
| mometasone furoate nasal spray | Organon | Approved | 80 |